PALB2 and breast cancer: For the first time, we estimated the lifetime health effects, costs, cost-effectiveness, and potential population impact of unselected BRCA1/BRCA2/PALB2 multigene testing for all BC patients compared to ‘FH/clinical-criteria-based BRCA testing’ and with ‘no testing’ in China.